COVID-19
In a fourth quarter 2020 financial results announcement made on Monday, Inovio Pharmaceuticals said it has completed enrollment of 400 participants in its Phase II segment of the INNOVATE (INOVIO INO-4800 Vaccine Trial for Efficacy) Phase II/III trial.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for March 2, 2021.
Novavax Chief Executive Officer Stanley Erck believes the U.S. Food and Drug Administration could grant Emergency Use Authorization for its COVID-19 vaccine by May.
What percentage of a population needs to be immune in order to achieve herd immunity is a matter of debate among scientists and public health officials.
The company has agreed to deliver 100 million doses of the vaccines by the end of June.
It was another busy week for clinical trial news. Here’s a look.
As the vaccines against COVID-19 are being rolled out worldwide, numerous studies are being conducted to evaluate how the vaccines do under less controlled situations. Here’s a look.
As scientists and vaccine manufacturers continue to test their products against the variants, researchers are seeing new variants cropping up that originated in the U.S.
The date set by the FDA’s independent advisors for debating that decision is Friday, February 26.
Even with its potential technical advantages, Novavax has some challenges.
PRESS RELEASES